Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Alpine Immune Sciences, Inc. is not a good value stock. Alpine Immune Sciences, Inc. is not a good growth stock. Alpine Immune Sciences, Inc. is not very popular among insiders. Alpine Immune Sciences, Inc. is a mediocre stock to choose.
Log in to see more information.
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the dis...
ALPN Fundamental Data by TradingView

News

Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors
Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors

Globe Newswire FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of...\n more…

Franklin Resources Inc. Takes Position in Alpine Immune Sciences, Inc. (NASDAQ:ALPN)
Franklin Resources Inc. Takes Position in Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

Ticker Report Franklin Resources Inc. bought a new stake in Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities &...\n more…

BNP Paribas Financial Markets Buys 93,423 Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN)
BNP Paribas Financial Markets Buys 93,423 Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

Ticker Report BNP Paribas Financial Markets grew its position in Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Free Report) by 691.1% during the fourth quarter, according to its most recent 13F filing with the SEC...\n more…

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Receives Consensus Rating of "Hold" from Analysts
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Receives Consensus Rating of "Hold" from Analysts

Ticker Report Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Get Free Report) has earned an average recommendation of "Hold" from the eleven ratings firms that are currently covering the stock, MarketBeat Ratings...\n more…

Alpine Immune Sciences (NASDAQ:ALPN) Stock Rating Reaffirmed by Wedbush
Alpine Immune Sciences (NASDAQ:ALPN) Stock Rating Reaffirmed by Wedbush

Zolmax Alpine Immune Sciences (NASDAQ:ALPN - Get Free Report)s stock had its "neutral" rating reissued by equities research analysts at Wedbush in a research report issued to clients and investors on...\n more…

Alpine Immune Sciences (NASDAQ:ALPN) Given "Neutral" Rating at Wedbush
Alpine Immune Sciences (NASDAQ:ALPN) Given "Neutral" Rating at Wedbush

Ticker Report Alpine Immune Sciences (NASDAQ:ALPN - Get Free Report)s stock had its "neutral" rating restated by investment analysts at Wedbush in a report issued on Thursday, Benzinga reports. They...\n more…